TACE术后联合斑蝥酸钠维生素B6治疗原发性肝癌患者近期疗效研究*

doi:10.3969/j.issn.1672-5069.2024.02.026

摘要/Abstract

摘要： 目的探讨肝动脉灌注化疗栓塞(TACE)术后联合斑蝥酸钠维生素B6治疗原发性肝癌(PLC)患者的近期疗效。方法 2019年1月～2022年1月我院收治的84例PLC患者, 对照组42例接受TACE治疗, 另42例观察组接受TACE术后联合斑蝥酸钠维生素B6静脉滴注治疗, 术后随访1年。采用化学荧光法检测血清甲胎蛋白(AFP)水平, 采用化学发光免疫分析法检测血清糖类抗原125(CA125)水平, 采用直接化学发光法检测血清糖类抗原199(CA199)水平, 采用酶法检测血清同型半胱氨酸(Hcy)水平, 采用硝酸盐还原法检测血清一氧化氮(NO)水平, 采用增强化学发光免疫分析法检测血清内皮素(ET-1)水平。结果观察组完全缓解率、部分缓解率、疾病稳定率和疾病进展率分别为7.1%、42.9%、38.1%和4.8%, 而对照组则分别为7.1%、40.5%、19.1%和26.2%, 其中观察组疾病稳定率显著高于对照组(P＜0.05);治疗后, 观察组血清AFP、CA125和CA199水平分别为(540.4±87.1)μg/L、(28.1±9.1)kU/L和(18.0±4.8)kU/L, 显著低于对照组【分别为(831.2±94.8)μg/L、(36.0±10.4)kU/L和(24.1±4.6)kU/L, P＜0.05】;观察组血清Hcy和ET-1水平分别为(14.1±3.6)μmol/L和(66.1±10.3)ng/L, 显著低于对照组【分别为(18.4±4.3)μmol/L和(80.2±12.1)ng/L, P＜0.05】;观察组胃肠道反应发生率为16.7%, 显著低于对照组的40.5%(P＜0.05);两组1 a生存率无显著性差异(84.2%对76.9%, P>0.05)。结论在TACE术后应用斑蝥酸钠维生素B6静脉滴注可以减轻胃肠道反应, 并可能改善内皮细胞功能。

关键词: 原发性肝癌, 肝动脉灌注化疗栓塞术, 斑蝥酸钠维生素B6, 治疗

Abstract: Objective This clinical trial was conducted to investigate the efficacy of venous administration of vitamin B6 sodium cantharidate after transhepatic arterial chemoembolization (TACE) in the treatment of patients with primary liver cancer (PLC). Methods 84 patients with PLC were encountered in our hospital between January 2019 and January 2022, and 42 patients in the control received TACE and another 42 patients in the observation were treated by TACE followed by venous administration of vitamin B6 sodium cantharidate for three weeks. All patients in the two groups were followed-up for one year. Serum alpha-fetoprotein (AFP) levels were detected by chemical fluorescence assay, serum carbohydrate antigen 125 (CA125) levels were detected by chemiluminescence immunoassay, and serum carbohydrate antigen 199 (CA199) levels were detected by direct chemiluminescence assay. Serum homocysteine (Hcy) levels were detected by enzymatic method, serum nitric oxide (NO) levels were assayed by nitrate reduction method, and serum endothelin (ET-1) levels were determined by enhanced chemiluminescence immunoassay. Results The CR, PR, SD and PD in the observation were 7.1%, 42.9%, 38.1% (P＜0.05) and 4.8%, while those in the control were 7.1%, 40.5%, 19.1% and 26.2%, with the SD significantly different between the two groups; after treatment, serum AFP, CA125 and CA199 levels in the observation group were (540.4±87.1)μg/L, (28.1±9.1)kU/L and (18.0±4.8)kU/L, all significantly lower than in the control; serum Hcy and ET-1 levels were (14.1±3.6)μmol/L and (66.1±10.3)ng/L, both much lower than [(18.4±4.3)μmol/L and (80.2±12.1)ng/L, respectively, P＜0.05] in the control; the incidence of gastrointestinal reaction in the observation was 16.7%, much lower than 40.5%(P＜0.05) in the control; there was no significant difference as respect to the one-year survival in the two groups (84.2% vs.76.9%, P>0.05). Conclusion The venous administration of vitamin B6 sodium cantharidate after TACE in the treatment of patients with PLC could ameliorate gastrointestinal reactions and improve the vascular endothelial functions.

Key words: Hepatoma, Transhepatic arterial chemoembolization, Vitamin B6 sodium cantharidate, Therapy

杨帆, 杨军, 濮忠健, 胡雪星. TACE术后联合斑蝥酸钠维生素B6治疗原发性肝癌患者近期疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 263-266.

Yang Fan, Yang Jun, Pu Zhongjian, et al.. Venous administration of vitamin B6 sodium cantharidate after TACE in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2024, 27(2): 263-266.

参考文献

[1] Liu BJ, Gao S, Zhu X, et al. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol, 2020, 12(6):663-676.
[2] Petrick JL, Florio AA, Znaor A,et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer, 2020, 147(2):317-330.
[3] Sun M, Shang P, Bai J, et al. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. J Clin Lab Anal, 2021, 35(2):e23633.
[4] Patkar S, Parray A, Mahendra B, et al. Performance of Hong Kong Liver Cancer staging system in patients of hepatocellular carcinoma treated with surgical resection: An Indian validation study. J Surg Oncol, 2019, 120(7):1119-1125.
[5] Liu YM, Ren YQ, Song SL, et al. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: etiological characteristics, treatment, and outcome analysis. Kaohsiung J Med Sci, 2023, 39(1):87-94.
[6] Grant WB .Comments on "Association of calcium and vitamin D supplementation with cancer incidence and cause-specific mortality inblack women: Extended follow-up of the Women's Health Initiative calcium-vitamin D trial".Int J Cancer, 2023, 153(2):450-451.
[7] 蒋峰,孙晓虹,高艺文,等.斑蝥酸钠维生素B6注射液联合不同化疗药物对晚期肝癌患者RBM38、SPATS2及预后的影响. 中西医结合肝病杂志, 2023, 33(3):237-241.
[8] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝脏病杂志, 2015, 23(5):321-327.
[9] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2):228-247.
[10] Wang LZ, Zhang HJ, Song J . Efficacy of mannatide combined with sodium cantharidate vitamin B6 in the treatment of malignant pleural effusions. Asian Pac J Cancer Prev, 2015, 16(9):3913-3916.
[11] Sun Y, Zhang D, Mao M, et al. Roles of p38 and JNK protein kinase pathways activated by compound cantharidin capsules containing serum on proliferation inhibition and apoptosis of human gastric cancer cell line. Exp Ther Med, 2017, 14(2):1809-1817.
[12] Chun J, Park MK, Ko H, et al. Bioassay-guided isolation of cantharidin from blister beetles and its anticancer activity through inhibition of epidermal growth factor receptor-mediated STAT3 and Akt pathways. J Nat Med, 2018, 72(4):937-945.
[13] Shao H, Hong G, Luo X . Evaluation of sodium cantharidinate/vitamin B6 in the treatment of primary liver cancer. J Cancer Res Ther, 2014, 10(1):75-78.
[14] Clasen JL, Heath AK, Van Puyvelde H, et al. A comparison of complementary measures of vitamin B6 status, function, and metabolism in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr, 2021, 114(1):338-347.
[15] Peng YF, Han MM, Huang R, et al. Vitamin B6intake and pancreatic carcinoma risk: A Meta-analysis. Nutr Cancer, 2019, 71(7):1061-1066.
[16] 裴颖,黄峰,殷宏振,等. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探. 实用肝脏病杂志, 2019, 22(4):486-489.
[17] 闫书鸣,王建国,李泽信,等. 门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究. 实用肝脏病杂志, 2018, 21(6):932-935.
[18] Fathy A, Abdelrahman AE . EZH2,endothelin-1, and CD34 as biomarkers of aggressive cervical squamous cell carcinoma: An immunohistochemical study. Turk Patoloji Derg, 2018, 34(2):150-157.
[19] Du Plessis JP, Lammertyn L, Schutte AE, et al. H-type hypertension among black south africans and the relationship between homocysteine, its genetic determinants and estimates of vascular function. J Cardiovasc Dev Dis, 2022, 9(12):447-447.
[20] Pusceddu I, Herrmann W, Kleber ME, et al. Subclinical inflammation, telomere shortening, homocysteine, vitamin B6, and mortality: the Ludwigshafenrisk and cardiovascular health study. Eur J Nutr, 2020, 59(4):1399-1411.
[21] Heilfort L, Kutschan S, Drfler J, et al. A systematic review of the benefit of B-vitamins as a complementary treatment in cancer patients. Nutr Cancer, 2023, 75(1):33-47.
[22] Babaei AH, Foghaha MH . A randomized comparison of vitamin B6 and dimenhydrinate in the treatment of nausea and vomiting in early pregnancy. Iran J Nurs Midwifery Res, 2014, 19(2):199-202.

TACE术后联合斑蝥酸钠维生素B6治疗原发性肝癌患者近期疗效研究^*

Venous administration of vitamin B6 sodium cantharidate after TACE in the treatment of patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[2]	李兴泉, 杨春, 李诗源, 翁凯, 彭麟. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 177-180.
[3]	于欣欣, 付朝霞, 薛莉. 减量索磷布韦联合全量达卡他韦治疗终末期肾病合并急性丙型肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 181-184.
[4]	李尧, 梁健, 张春, 董静, 陈照林, 周旭, 娄方明, 杨小康, 刘波, 宋海燕. 恩替卡韦联合聚乙二醇干扰素-α2b治疗代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2024, 27(2): 226-229.
[5]	王红霞, 胥晓倩, 于明帅. 内镜下硬化剂治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者应用不同剂量羟考酮联合丙泊酚靶控输注麻醉效果研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 230-233.
[6]	万贵香, 李忠廉, 赵亚博, 梁微微, 杜辉, 宁振海, 周媛, 万亮. 恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 234-237.
[7]	肖潇, 盛云建. 内镜下曲张静脉套扎术联合经颈静脉肝内门体静脉分流术治疗肝硬化食管胃底静脉曲张破裂出血患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 238-241.
[8]	谢晶美, 刘浩, 李安, 李华, 陈苗苗, 郭宝琴, 石洋洋, 朱志敏, 郭晨光. 动态增强MRI定量参数术前评估原发性肝癌患者临床分期研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 255-258.
[9]	付彦爽, 陈晓丽, 付彦青, 冯静. MWA联合抗PD-1抗体治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 259-262.
[10]	王莹莹, 周平, 程蕾. 右美托咪定复合七氟醚麻醉接受肝叶切除术治疗原发性肝癌患者麻醉效果分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 267-270.
[11]	张亚龙, 胡冬梅, 赵晟, 孟海生. 超声引导下射频消融治疗小原发性肝癌疗效及死亡危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 271-274.
[12]	王秀香, 李海霞, 李辉, 王明月, 代树本, 于晓明. DEB-TACE序贯微波消融术治疗大原发性肝癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 283-286.
[13]	贾江坤, 余淼, 贾萌, 徐健, 王佳佳, 宋红霞, 申权, 薛焕洲, 陈旭晓. 腹腔镜辅助下血管瘤剥除术与解剖性肝切除术治疗巨大肝血管瘤疗效比较^*[J]. 实用肝脏病杂志, 2024, 27(2): 287-290.
[14]	何晓非, 陈杰, 罗国松, 陆世峰. ERCP治疗急性梗阻性化脓性胆管炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 291-294.
[15]	唐昊, 杨天福. 腹腔镜胆总管探查术联合经腹直肌引出T管与经右锁骨中线引出引流治疗胆总管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 295-298.